TITILAYO AKINSOLA: Open Payments
NPI 1902371321 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$963 in 28 payments from 8 companies in 2025. Trend: 2023 $77 · 2024 $275 · 2025 $963
Food & beverage: $963
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $215 |
| Alkermes, Inc. | 3 | $159 |
| Supernus Pharmaceuticals, Inc. | 4 | $158 |
| E.R. Squibb & Sons, L.L.C. | 3 | $141 |
| Janssen Pharmaceuticals, Inc | 3 | $103 |
| Neurocrine BioSciences, Inc. | 1 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: VRAYLAR, Qelbree, LYBALVI, COBENFY, INVEGA SUSTENNA, INGREZZA, REXULTI, ABILIFY MAINTENA.
Industry payments across MD — which companies pay providers there.
